vildagliptin + empagliflozin + metformin

vildagliptin + empagliflozin + metformin is a fixed-dose triple combination therapy being developed for the management of type 2 diabetes mellitus. This formulation integrates three anti-hyperglycemic agents with distinct and complementary mechanisms of action: vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion; empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that promotes glucose excretion via the kidneys; and metformin, a biguanide that reduces hepatic glucose production and improves insulin sensitivity. The developer, Guangzhou Yueyang Pharmaceutical Development (also known as TransThera), utilizes specialized drug delivery technology to create a sustained-release version of this triple combination. This approach aims to simplify complex treatment regimens, improve patient compliance, and provide more stable glycemic control compared to the administration of individual components.

Other names

vildagliptin/empagliflozin/metforminvildagliptin/empagliflozin/metformin hydrochloride sustained-release tablets维格列汀恩格列净二甲双胍缓释片